Maternal serum irisin levels in early and late-onset pre-eclamptic and healthy pregnancies

Abstract The aim of the study was to investigate whether plasma irisin concentrations differ between uncomplicated, early-onset and late-onset pre-eclamptic pregnancies. This cross-sectional study was conducted on 27 women with early-onset, 27 women with late-onset pre-eclampsia (PE) and 26 healthy pregnant women. Maternal levels of serum irisin were measured with the use of an enzyme-linked immunosorbent assay kit. The mean maternal serum irisin level of early-onset PE was significantly lower than late-onset PE (1.14 ± 0.56 vs. 1.46 ± 0.59, p < .05) and control subjects (1.14 ± 0.56 vs. 3.14 ± 0.81, p < 0.001). The mean maternal serum irisin level of late-onset PE was significantly lower than the control group (1.46 ± 0.59 vs. 3.14 ± 0.81, p < 0.001). Maternal serum irisin levels are decreased in pre-eclamptic pregnancies. Low levels of irisin may be the result or the cause of pathologic changes in PE. Impact statement What is already known on this subject? There are only two studies in the literature evaluating maternal serum irisin levels in pre-eclamptic pregnancies. One study demonstrated decreased maternal serum irisin levels in pre-eclamptic patients and the other found no significant difference between pre-eclamptic and control pregnancies. What do the results of this study add? The present study demonstrates that serum irisin levels were significantly lower in pre-eclampsia than normotensive pregnancies. Furthermore, we have also demonstrated for the first time that women with EO-PE had significantly lower levels of serum irsin than women with LO-PE. What are the implications of these findings for clinical practice and/or further research? Low levels of irisin may be the result or the cause of pathologic changes in pre-eclampsia. More studies are needed to evaluate the relationship between irisin and pre-eclampsia.

[1]  Ai-hua Zhang,et al.  Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia , 2017, Clinical and experimental hypertension.

[2]  X-L Du,et al.  Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2016, Hormone and Metabolic Research.

[3]  Junfeng Zhang,et al.  Lower irisin level in patients with type 2 diabetes mellitus: A case‐control study and meta‐analysis , 2016, Journal of diabetes.

[4]  F. Wang,et al.  Irisin relaxes mouse mesenteric arteries through endothelium-dependent and endothelium-independent mechanisms. , 2015, Biochemical and biophysical research communications.

[5]  W. Mitch,et al.  Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues , 2015, International Journal of Obesity.

[6]  Xiaodong Sun,et al.  The relationship between circulating irisin levels and endothelial function in lean and obese subjects , 2015, Clinical endocrinology.

[7]  Soo-Hyun Park,et al.  New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro. , 2015, Cellular signalling.

[8]  D. Nelson,et al.  Placental pathology suggesting that preeclampsia is more than one disease. , 2014, American journal of obstetrics and gynecology.

[9]  N. Çolakoğlu,et al.  A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues , 2014, Peptides.

[10]  Junxia Zhang,et al.  Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. , 2014, Atherosclerosis.

[11]  M. Oncul,et al.  Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. , 2014, Diabetes research and clinical practice.

[12]  J. Eslava-Schmalbach,et al.  Irisin levels during pregnancy and changes associated with the development of preeclampsia. , 2014, The Journal of clinical endocrinology and metabolism.

[13]  M. Oncul,et al.  Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia , 2014, Archives of Gynecology and Obstetrics.

[14]  J. Moreno-Navarrete,et al.  Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  M. Febbraio,et al.  Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.

[16]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[17]  D. Raymond,et al.  A Critical Review of Early-Onset and Late-Onset Preeclampsia , 2011, Obstetrical & gynecological survey.

[18]  A. Ragab,et al.  Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings? , 2010, Archives of Gynecology and Obstetrics.

[19]  S. Hauguel-de Mouzon,et al.  The placenta cytokine network and inflammatory signals. , 2006, Placenta.

[20]  P. Catalano,et al.  Factors that affect maternal insulin resistance and modify fetal growth and body composition. , 2006, Metabolic syndrome and related disorders.

[21]  F. Dunne,et al.  Oxidative stress and normal pregnancy , 2002, Clinical endocrinology.

[22]  J. Roberts,et al.  Recent Insights into the pathogenesis of pre-eclampsia. , 2002, Placenta.

[23]  Diagnosis and management of preeclampsia and eclampsia , 2002 .

[24]  M. Ruth A PGC1–α–dependent myokine that drives brown–fat–like development of white fat and thermogenesis , 2012 .